Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

AIMS: To examine the efficacy and safety of once‐weekly dulaglutide monotherapy (0.75 mg) compared with placebo and once‐daily liraglutide (0.9 mg) in Japanese patients with type 2 diabetes. METHODS: This was a phase III, 52‐week (26‐week primary endpoint), randomized, double‐blind, placebo‐controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagawa, J., Odawara, M., Takamura, T., Iwamoto, N., Takita, Y., Imaoka, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042083/
https://www.ncbi.nlm.nih.gov/pubmed/26179187
http://dx.doi.org/10.1111/dom.12534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042083/
https://www.ncbi.nlm.nih.gov/pubmed/26179187
http://dx.doi.org/10.1111/dom.12534

Ejemplares similares